Stock events for Danaher Corp. (DHR)
Over the past six months, Danaher's stock price has experienced a decline. Analyst rating adjustments included RBC Capital cutting Danaher's price target from $250 to $241, while Bank of America lowered its target from $230 to $220. Beckman Coulter Diagnostics launched the fully automated BD-Tau immunoassay test for neurodegenerative research. Danaher reported Q2 2025 earnings exceeding analyst expectations and declared a regular quarterly dividend of $0.32 per share. Insider Teri List sold 2,778 shares of Danaher stock. Jim Cramer expressed concern over Danaher's recent performance.
Demand Seasonality affecting Danaher Corp.’s stock price
Demand for Danaher's products and services can exhibit some seasonality, with margins potentially facing short-term pressure in Q3. The company has experienced inventory destocking among its bioprocessing customers, impacting consumable demand, and a decline in sales of COVID-19 related products has led to a decrease in revenue. Recovery in the Chinese market is expected to be gradual, but underlying demand in healthcare and life sciences remains solid, supporting longer-term growth.
Overview of Danaher Corp.’s business
Danaher Corporation is a global science and technology innovator specializing in life sciences, diagnostics, and environmental and applied solutions, operating primarily within the healthcare sector. The company's business is structured around three main segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment focuses on advancing therapeutic development and manufacturing, offering bioprocess technologies and related services. The Life Sciences segment provides tools and technologies for scientific research and discovery, including mass spectrometry systems and genomics tools. The Diagnostics segment delivers solutions to improve patient care and healthcare efficiency, encompassing clinical diagnostic instruments and services. Danaher also has an Environmental & Applied Solutions segment, which offers products and services related to water quality testing and treatment, product identification systems, and environmental monitoring tools.
DHR’s Geographic footprint
Danaher Corporation has a worldwide geographic footprint, serving pharmaceutical and biotechnology companies, healthcare providers, and research institutions across the Americas, Europe, the Middle East, Africa, and Asia-Pacific through independent distributors. The company also maintains manufacturing facilities in Europe, Australia, Asia, and the Americas.
DHR Corporate Image Assessment
Danaher generally maintains a strong brand reputation, recognized for its management and market leadership, and was listed among Forbes' "Most Trusted Companies in America" in 2025. However, the company's recent performance has faced scrutiny from analysts and media, with challenges related to projected revenue, particularly due to a decline in respiratory sales and pricing pressures in China. The launch of the BD-Tau immunoassay test could positively impact Danaher's reputation for innovation.
Ownership
Danaher Corporation's ownership is largely institutional, with institutional investors holding approximately 74% of the company's shares. Top institutional holders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Key individual insiders with significant holdings include Steven M. Rales, who owns 13.01% of the company, and Mitchell P. Rales, owning 11.86%.
Ask Our Expert AI Analyst
Price Chart
$206.15